Please login to the form below

Not currently logged in
Email:
Password:

Provenge

This page shows the latest Provenge news and features for those working in and with pharma, biotech and healthcare.

Valeant uncouples Dendreon and skincare brands to cut debt

Valeant uncouples Dendreon and skincare brands to cut debt

Agrees deals worth $2.1bn with L’Oreal and Sanpower Group. Dendreon's Provenge cancer vaccine. ... Meanwhile, the Dendreon deal comes two years after Valeant paid around $300m for the business, which sells Provenge, an autologous cellular immunotherapy

Latest news

More from news
Approximately 9 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Vaccines. While the first therapeutic cancer vaccines have reached the market, eg Dendreon’s Provenge and Antigenics’ Oncophage, commercially they haven’t yet made much impact and the pipeline has been

  • Deal Watch January 2017 Deal Watch January 2017

    Bringing in an additional $819.9m in cash, Valeant also sold its equity interest in Dendreon (manufacturer of Provenge, a personalised immunotherapy) to the Sanpower Group.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Corporate acquisition. 400. Dendreon/ Valeant Pharmaceuticals. PROVENGE (sipuleucel-T) and other assets - prostate cancer.

  • Pharma deals in February 2015 Pharma deals in February 2015

    This month saw the deadline, highlighted in January's Deal Watch, for Valeant to acquire Dendreon, and more specifically the dendritic cell, prostate cancer vaccine Provenge (sipuleucel-T), come and go.

  • Pharma deals during January 2015 Pharma deals during January 2015

    Staying with immuno-oncology, an acquisition in the making is the stalking horse bid of $400m cash from Valeant to acquire the rights to Dendreon's Provenge (sipuleucel-T) which are

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    The appointment comes at a time when the Californian biopharma drives to expand the use of Provenge (sipuleucel-T). ... Bruce’s valuable background leading major medical organisations makes him the ideal fit to accelerate our R&D programme and oversee

  • Dendreon CEO to step down Dendreon CEO to step down

    John Johnson to leave next summer as Provenge sales stall. Dendreon has announced that CEO John Johnson will leave the company in August next year. ... According to the company's financial report, sales of Provenge declined from $325m in 2012 to $286m in

  • AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

    prostate cancer vaccine Provenge.

  • Lindsay Rocco to lead corporate communications at Dendreon Lindsay Rocco to lead corporate communications at Dendreon

    The US biotech, which markets prostate cancer vaccine Provenge (sipuleucel-T), said Rocco will be responsible for all communications functions of the company, reporting directly to chair, president and CEO John

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics